24-hour Serial Spirometric Assessment of Once-Daily Fluticasone furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study

figure

posted on 2020-09-28, 10:22 authored by David A Lipson, Ruby Birk, Noushin Brealey, Chang-Qing Zhu

<p>The above Summary Slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).<br></p> © The authors, CC-BY-NC 2020.<b></b>

Funding

GlaxoSmithKline

History

Related Materials

1.
URL - References https://link.springer.com/article/10.1007/s12325-020-01496-7
2.
DOI - Is supplement to 24-hour Serial Spirometric Assessment of Once-Daily Fluticasone furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study

Usage metrics

Advances in Therapy

Categories

Keywords

Chronic obstructive pulmonary disease Lung function Single-inhaler triple therapy Long-acting β2-agonist Long-acting muscarinic antagonist Inhaled corticosteroid Serial FEV1

Licence

Exports